journal
MENU ▼
Read by QxMD icon Read
search

Multiple Sclerosis Journal—Experimental, Translational and Clinical

journal
https://www.readbyqxmd.com/read/29977589/patient-perceived-changes-in-sexual-dysfunction-after-initiation-of-natalizumab-for-multiple-sclerosis
#1
Derrick Robertson, Angela Aungst, Ryan Collier, Jhulianna Vivar, Natalie Moreo, Lise Casady, Tuan Vu
Purpose: Sexual dysfunction is a common but often overlooked secondary symptom of multiple sclerosis (MS) and can be associated with a decreased health-related quality of life (HRQoL). Natalizumab is a disease-modifying therapy approved for the treatment of relapsing forms of MS. In addition to its efficacy, those using natalizumab have shown improvement in HRQoL parameters, including fatigue and cognition. The idea that improvement in fatigue may also correlate with improvement in sexual dysfunction is the impetus for this study...
April 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29900003/novel-computer-based-testing-shows-multi-domain-cognitive-dysfunction-in-patients-with-multiple-sclerosis
#2
Andrew D Smith, Charles Duffy, Andrew D Goodman
Background: Although cognitive dysfunction is a leading cause of disability and poor quality of life in patients with multiple sclerosis (MS), it is infrequently tested in routine clinical evaluation. Development of a cognitive testing paradigm that captured MS-related cognitive dysfunction and could be obtained in a routine clinical setting may increase surveillance and recognition of cognitive dysfunction. Objectives: This was a pilot study to determine if Cognivue could find cognitive performance differences between patients with MS and healthy controls (HC)...
April 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29854416/relapse-rate-and-mri-activity-in-young-adult-patients-with-multiple-sclerosis-a-post-hoc-analysis-of-phase-3-fingolimod-trials
#3
Jutta Gärtner, Tanuja Chitnis, Angelo Ghezzi, Daniela Pohl, Wolfgang Brück, Dieter Adrian Häring, Goeril Karlsson, Norman Putzki
Background: Disease activity differs in young patients with multiple sclerosis (MS) compared with the overall adult MS population. Objective: The objective of this paper is to evaluate the effect of fingolimod 0.5 mg on disease activity in young adults with MS from three randomized, double-blind Phase 3 trials. Methods: Annualized relapse rate (ARR), number of new/newly enlarging T2 lesions (neT2), and no evidence of disease activity (NEDA-3) were estimated in the intent-to-treat population at age 20 (youngest) and 30 (young) and compared to the overall population...
April 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29854415/patient-reported-disease-modifying-therapy-adherence-in-the-clinic-a-reliable-metric
#4
Devon S Conway, Maria Cecilia Vieira, Nicolas R Thompson, Kaila N Parker, Xiangyi Meng, Robert J Fox
Background: Adherence to multiple sclerosis (MS) disease-modifying therapy (DMT) is commonly assessed through patient reporting, but patient-reported adherence is rarely studied. Objective: To determine rates of DMT adherence reported from patient to clinician, reasons for nonadherence, and relationships between adherence and outcomes. Methods: We identified relapsing-remitting MS patients on DMT for ≥3 months. DMT adherence was defined as taking ≥80% of doses...
April 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29796290/addressing-the-targeting-range-of-the-abilhand-56-in-relapsing-remitting-multiple-sclerosis-a-mixed-methods-psychometric-study
#5
Sophie Cleanthous, Sara Strzok, Farrah Pompilus, Stefan Cano, Patrick Marquis, Stanley Cohan, Myla D Goldman, Kiren Kresa-Reahl, Jennifer Petrillo, Carmen Castrillo-Viguera, Diego Cadavid, Shih-Yin Chen
Background: ABILHAND, a manual ability patient-reported outcome instrument originally developed for stroke patients, has been used in multiple sclerosis clinical trials; however, psychometric analyses indicated the measure's limited measurement range and precision in higher-functioning multiple sclerosis patients. Objective: The purpose of this study was to identify candidate items to expand the measurement range of the ABILHAND-56, thus improving its ability to detect differences in manual ability in higher-functioning multiple sclerosis patients...
April 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29796289/clinical-efficacy-of-teriflunomide-over-a-fixed-2-year-duration-in-the-tower-study
#6
Mark S Freedman, Julia Morawski, Karthinathan Thangavelu
Patients enrolled in the phase 3 TOWER study (NCT00751881) of teriflunomide had variable treatment durations (48-173 weeks). This has led to challenges when interpreting results in the context of other phase 3 trials of disease-modifying therapies for multiple sclerosis, which typically have a fixed 2-year duration. This communication reports clinical outcomes in TOWER over a fixed 2-year period. Reductions in annualised relapse rates and 12-week confirmed disability worsening associated with teriflunomide were comparable between overall intent-to-treat and fixed 2-year study populations in TOWER...
April 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29780612/the-sound-of-jacqueline-du-pr%C3%A3-revisiting-her-medical-and-musical-history
#7
REVIEW
Luis Octavio Tierradentro-García, Juan Sebastián Botero-Meneses, Claudia Talero-Gutiérrez
Jacqueline du Pré was a British cellist, famous for her masterful interpretations and her passionate style of playing. Her outstanding musical career was, unfortunately, cut short by multiple sclerosis. In the present paper, we conduct a historical and medical analysis of her life story, discussing a few aspects regarding her illness and treatment options available at the time of her diagnosis.
April 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29780611/myelin-status-is-associated-with-change-in-functional-mobility-following-slope-walking-in-people-with-multiple-sclerosis
#8
E M King, M J Sabatier, M Hoque, T M Kesar, D Backus, M R Borich
Background: The level of myelin disruption in multiple sclerosis patients may impact the capacity for training-induced neuroplasticity and the magnitude of therapeutic response to rehabilitation interventions. Downslope walking has been shown to increase functional mobility in individuals with multiple sclerosis, but it is unclear if myelin status influences therapeutic response. Objective: The current study aimed to examine the relationship between baseline myelin status and change in functional mobility after a walking intervention...
April 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29780610/a-randomised-controlled-clinical-trial-of-narrowband-uvb-phototherapy-for-clinically-isolated-syndrome-the-phocis-study
#9
Prue H Hart, Anderson P Jones, Stephanie Trend, Lilian Cha, Marzena J Fabis-Pedrini, Matthew N Cooper, Catherine d'Este, Sian Geldenhuys, William M Carroll, Scott N Byrne, David R Booth, Judith M Cole, Robyn M Lucas, Allan G Kermode
Background: The natural history of multiple sclerosis (MS) typically presents with the clinically isolated syndrome (CIS), an episode of neurological symptoms caused by central nervous system inflammation or demyelination that does not fulfil the diagnostic criteria for MS. Objective: As preclinical studies have suggested that exposure to ultraviolet radiation (UVR) could regulate the development of MS, the Phototherapy for CIS (PhoCIS trial) was established to examine the effects of narrowband UVB phototherapy on patients with CIS, and their conversion to MS...
April 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29780609/serum-heat-shock-protein-70-levels-as-a-biomarker-for-inflammatory-processes-in-multiple-sclerosis
#10
Patricia Lechner, Dorothea Buck, Lisa Sick, Bernhard Hemmer, Gabriele Multhoff
Background: Inflammatory and neurodegenerative processes are hallmarks of multiple sclerosis (MS). The synthesis of the major stress-inducible heat shock protein 70 (Hsp70) is induced by inflammation. Objective: The purpose of this study is to determine whether Hsp70 in serum can serve as a potential biomarker to distinguish inflammatory and neurodegenerative processes in MS. Methods: Serum was obtained from 94 patients: 26 clinically isolated syndrome (CIS), 40 relapsing-remitting MS (RRMS), 19 secondary progressive MS (SPMS), and nine primary progressive MS (PPMS)...
April 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29707228/multiple-sclerosis-executive-dysfunction-task-switching-and-the-role-of-attention
#11
M Clough, P Foletta, A N Frohman, D Sears, A Ternes, O B White, J Fielding
Background: It has been suggested that switching ability might not be affected in multiple sclerosis (MS) as previously thought; however, whether this is true under more 'real-world' conditions when asymmetry in task difficulty is present has not been ascertained. Objective: The objective of this paper is to examine the impact of task difficulty asymmetry on task switching ability in MS. Method: An ocular motor (OM) paradigm that interleaves the simple task of looking towards a target (prosaccade, PS) with the cognitively more difficult task of looking away from a target (antisaccade, PS) was used...
April 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29662683/coexistence-of-systemic-lupus-erythematosus-and-multiple-sclerosis-a-case-report-and-literature-review
#12
REVIEW
Elisa Carolina Jácome Sánchez, María Ariana García Castillo, Victor Paredes González, Fernando Guillén López, Edgar Patricio Correa Díaz
Multiple sclerosis (MS) and systemic lupus erythematous (SLE) are autoimmune diseases, the coexistence of which is uncommon in patients. Owing to the rarity of this condition, the distinction between MS and SLE is a diagnostic challenge for neurologists. We present a case report in which MS and SLE were present in the same patient. There are few case reports in the world on the association between MS and SLE. The following case report is the first of its kind in which both MS and SLE are present in a patient from a country with low prevalence of MS such as Ecuador...
April 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29623216/feasibility-of-mesenchymal-stem-cell-culture-expansion-for-a-phase-i-clinical-trial-in-multiple-sclerosis
#13
Sarah M Planchon, Karen T Lingas, Jane Reese Koç, Brittney M Hooper, Basabi Maitra, Robert M Fox, Peter B Imrey, Kylie M Drake, Micheala A Aldred, Hillard M Lazarus, Jeffrey A Cohen
Background: Multiple sclerosis is an inflammatory, neurodegenerative disease of the central nervous system for which therapeutic mesenchymal stem cell transplantation is under study. Published experience of culture-expanding multiple sclerosis patients' mesenchymal stem cells for clinical trials is limited. Objective: To determine the feasibility of culture-expanding multiple sclerosis patients' mesenchymal stem cells for clinical use. Methods: In a phase I trial, autologous, bone marrow-derived mesenchymal stem cells were isolated from 25 trial participants with multiple sclerosis and eight matched controls, and culture-expanded to a target single dose of 1-2 × 106 cells/kg...
January 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29568544/no-evidence-of-disease-activity-neda-analysis-by-epochs-in-patients-with-relapsing-multiple-sclerosis-treated-with-ocrelizumab-vs-interferon-beta-1a
#14
Eva Havrdová, Douglas L Arnold, Amit Bar-Or, Giancarlo Comi, Hans-Peter Hartung, Ludwig Kappos, Fred Lublin, Krzysztof Selmaj, Anthony Traboulsee, Shibeshih Belachew, Iain Bennett, Regine Buffels, Hideki Garren, Jian Han, Laura Julian, Julie Napieralski, Stephen L Hauser, Gavin Giovannoni
Background: No evidence of disease activity (NEDA; defined as no 12-week confirmed disability progression, no protocol-defined relapses, no new/enlarging T2 lesions and no T1 gadolinium-enhancing lesions) using a fixed-study entry baseline is commonly used as a treatment outcome in multiple sclerosis (MS). Objective: The objective of this paper is to assess the effect of ocrelizumab on NEDA using re-baselining analysis, and the predictive value of NEDA status. Methods: NEDA was assessed in a modified intent-to-treat population ( n  = 1520) from the pooled OPERA I and OPERA II studies over various epochs in patients with relapsing MS receiving ocrelizumab (600 mg) or interferon beta-1a (IFN β-1a; 44 μg)...
January 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29552356/prolonged-release-fampridine-as-adjunct-therapy-to-active-motor-training-in-ms-patients-a-pilot-double-blind-randomized-placebo-controlled-study
#15
François Jacques, Adrian Schembri, Avi Nativ, Chantal Paquette, Pawel Kalinowski
Background: Both prolonged-release fampridine (PRF) and enabling active motor training (EAMT) are beneficial in multiple sclerosis (MS) patients. Their combined effect is, however, understudied. Objective: The objective of this paper is to determine if PRF augments the beneficial effect of EAMT in MS patients as opposed to placebo. Method: This is a pilot, randomized, placebo-controlled, double-blind 14-week study. Participants were randomly assigned to receive PRF 10 mg BID ( n  = 21) or placebo ( n  = 20)...
January 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29552355/severe-aquaporin-4-igg-positive-neuromyelitis-optica-with-disseminated-herpes-zoster-in-a-pregnant-woman-successfully-treated-with-intravenous-immunoglobulin
#16
Yuki Matsumoto, Mario Tsuchiya, Shakespear Norshalena, Chikako Kaneko, Jin Kubo, Teiji Yamamoto, Toshiyuki Takahashi, Kazuo Fujihara
A 26-year-old, 17-week pregnant woman developed aquaporin-4-IgG-positive severe longitudinally extensive transverse myelitis during the course of disseminated herpes zoster and became quadriparetic. She was unresponsive to high-dose intravenous methylprednisolone but became able to walk without assistance after intravenous immunoglobulin. One and a half months later, left optic neuritis developed but her vision improved with intravenous immunoglobulin. The only sequela was left T5 girdle sensation, and she delivered a healthy baby...
January 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29497559/treadmill-walking-exercise-training-and-brain-function-in-multiple-sclerosis-preliminary-evidence-setting-the-stage-for-a-network-based-approach-to-rehabilitation
#17
Brian M Sandroff, Glenn R Wylie, Brad P Sutton, Curtis L Johnson, John DeLuca, Robert W Motl
Exercise training has been identified as a highly promising approach for managing the cognitive consequences of multiple sclerosis (MS). This study represents a secondary analysis of resting-state functional connectivity (RSFC) magnetic resonance imaging data from a pilot treadmill walking exercise training intervention for improving cognitive processing speed (CPS) in MS. There were large intervention effects on RSFC between the thalamus and right superior frontal gyrus ( d  = 1.92) and left medial frontal gyrus ( d  = 1...
January 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29497558/risk-factors-for-fingolimod-induced-lymphopenia-in-multiple-sclerosis
#18
Ryohei Ohtani, Masahiro Mori, Tomohiko Uchida, Akiyuki Uzawa, Hiroki Masuda, Jia Liu, Satoshi Kuwabara
Background: Lymphopenia is a well-known adverse event of fingolimod, a disease-modifying drug for multiple sclerosis (MS). Objectives: The objective of this paper is to investigate risk factors for predicting fingolimod-induced lymphopenia in MS by frequent hematological monitoring. Methods: We retrospectively reviewed data of fingolimod-treated MS patients. Data assessed were sex, age, disease duration, medication history, body mass index, all attacks, Kurtzke's Expanded Disability Status Scale score, and absolute lymphocyte count (ALC) within two days before initiating fingolimod (baseline), on the day after first administration (day 2), and at least every other month after initiating fingolimod therapy...
January 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29479457/a-randomized-study-to-evaluate-the-effect-of-exercise-on-fatigue-in-people-with-relapsing-remitting-multiple-sclerosis-treated-with-fingolimod
#19
M Mäurer, K Schuh, S Seibert, M Baier, C Hentschke, R Streber, A Tallner, K Pfeifer
Background: Fatigue is a major symptom of multiple sclerosis (MS) in patients, and it has been shown to improve with physical exercise. Although fingolimod might lessen fatigue, it is unclear how patients treated with fingolimod react to physical activity regarding fatigue. Objective: This study evaluated the effect of an exercise intervention on fatigue in relapsing-remitting MS patients receiving fingolimod. Methods: People with MS (PwMS) were randomized to either a structured internet-based exercise program (e-training) or no e-training intervention...
January 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
https://www.readbyqxmd.com/read/29383266/movement-measurements-at-home-for-multiple-sclerosis-walking-speed-measured-by-a-novel-ambient-measurement-system
#20
Victoria Mj Smith, Jonathan S Varsanik, Rachel A Walker, Andrew W Russo, Kevin R Patel, Wendy Gabel, Glenn A Phillips, Zebadiah M Kimmel, Eric C Klawiter
Background: Gait disturbance is a major contributor to clinical disability in multiple sclerosis (MS). A sensor was developed to assess walking speed at home for people with MS using infrared technology in real-time without the use of wearables. Objective: To develop continuous in-home outcome measures to assess gait in adults with MS. Methods: Movement measurements were collected continuously for 8 months from six people with MS. Average walking speed and peak walking speed were calculated from movement data, then analyzed for variability over time, by room (location), and over the course of the day...
January 2018: Multiple Sclerosis Journal—Experimental, Translational and Clinical
journal
journal
52506
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"